Ftse Mib
33.629,21
-0,32%
DAX
18.001,60
0,54%
S&P 500
5.127,79
1,26%
NASDAQ
16.156,33
1,99%
Bitcoin
63.879,33
1,57%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Psychemedics Corporation (PMD) Psychemedics Corporation (PMD) Notizie

Psychemedics Corporation

PMD
2,55
-0,0863 (-3,27%)
04 Mag 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
28/3/202413:20GLOBEPsychemedics Corporation Reports 2023 Financial Results
21/3/202414:00GLOBEPsychemedics Recognized as a Top 10 Employee Health Testing..
13/2/202415:43EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
02/2/202422:05EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
26/1/202422:10EDGAR2Form 8-K - Current report
24/1/202423:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/1/202417:27GLOBEPsychemedics Corporation Announces Relocation of..
19/12/202322:59EDGAR2Form 3 - Initial statement of beneficial ownership of..
14/12/202318:56EDGAR2Form SC 13G - Statement of acquisition of beneficial..
27/11/202317:31EDGAR2Form 8-K - Current report
27/11/202315:00GLOBEPsychemedics Corporation Appoints Daniella Mehalik as VP -..
13/11/202323:16EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/11/202323:00GLOBEPsychemedics Corporation Reports Third Quarter 2023..
09/11/202323:00EDGAR2Form 8-K - Current report
08/11/202323:00EDGAR2Form 8-K - Current report
27/10/202317:00GLOBEUnveiling the Future of Drug Testing: Psychemedics..
26/9/202300:29EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/9/202319:00EDGAR2Form 8-K - Current report
21/9/202323:00GLOBEPsychemedics Corporation Appoints Shannon Shoemaker as Chief..
31/8/202323:20EDGAR2Form 8-K - Current report
22/8/202323:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/8/202323:01EDGAR2Form S-8 - Securities to be offered to employees in employee..
21/8/202323:48EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/8/202323:48EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/8/202323:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/8/202323:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/8/202323:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/8/202323:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/8/202323:01EDGAR2Form 8-K - Current report
18/8/202320:00GLOBEPsychemedics Corporation Reports Inducement Grants Under..
17/8/202323:30EDGAR2Form 144 - Report of proposed sale of securities
14/8/202323:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11/8/202323:10GLOBEPsychemedics Corporation Reports Second Quarter 2023..
11/8/202323:10EDGAR2Form 8-K - Current report
21/7/202323:00EDGAR2Form 8-K - Current report
21/7/202322:00EDGAR2Form DEF 14A - Other definitive proxy statements
14/7/202315:15EDGAR2Form 8-K - Current report
12/7/202323:15GLOBEPsychemedics Corporation Announces CEO Succession Plan
09/5/202323:30GLOBEPsychemedics Corporation Reports First Quarter 2023..
Apertura: 2,64 Min: 2,53 Max: 2,64
Chiusura: 2,6363

La tua Cronologia

NASDAQ
PMD
Psychemedics
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network